Trial Profile
A phase III, double-blind, comparative study of NE-58095 (once-monthly formulation)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 May 2016
Price :
$35
*
At a glance
- Drugs Risedronic acid (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- Sponsors Takeda
- 24 May 2016 New trial record